- Home
- OSUR vs TLSI Comparison
OSUR vs TLSI Comparison
Compare OSUR & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSUR
- TLSI
- Stock Information
- Founded
- OSUR 2000
- TLSI 2010
- Country
- OSUR United States
- TLSI United States
- Employees
- OSUR N/A
- TLSI N/A
- Industry
- OSUR Medical/Dental Instruments
- TLSI Medical Specialities
- Sector
- OSUR Health Care
- TLSI Health Care
- Exchange
- OSUR Nasdaq
- TLSI Nasdaq
- Market Cap
- OSUR 231.1M
- TLSI 244.3M
- IPO Year
- OSUR 1986
- TLSI N/A
- Fundamental
- Price
- OSUR $2.88
- TLSI $5.13
- Analyst Decision
- OSUR Hold
- TLSI Strong Buy
- Analyst Count
- OSUR 1
- TLSI 4
- Target Price
- OSUR $3.00
- TLSI $11.13
- AVG Volume (30 Days)
- OSUR 487.9K
- TLSI 123.2K
- Earning Date
- OSUR 11-07-2025
- TLSI 11-13-2025
- Dividend Yield
- OSUR N/A
- TLSI N/A
- EPS Growth
- OSUR N/A
- TLSI N/A
- EPS
- OSUR N/A
- TLSI N/A
- Revenue
- OSUR $138,533,000.00
- TLSI $35,990,000.00
- Revenue This Year
- OSUR N/A
- TLSI $56.71
- Revenue Next Year
- OSUR $4.32
- TLSI $52.25
- P/E Ratio
- OSUR N/A
- TLSI N/A
- Revenue Growth
- OSUR N/A
- TLSI 45.50
- 52 Week Low
- OSUR $2.36
- TLSI $3.42
- 52 Week High
- OSUR $4.60
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- OSUR 35.27
- TLSI 59.27
- Support Level
- OSUR $2.94
- TLSI $4.39
- Resistance Level
- OSUR $3.14
- TLSI $5.33
- Average True Range (ATR)
- OSUR 0.11
- TLSI 0.28
- MACD
- OSUR -0.03
- TLSI 0.07
- Stochastic Oscillator
- OSUR 0.00
- TLSI 82.46
About OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.